| Next 10 |
AGLE News and Press, Aeglea BioTherapeutics Inc.
-
Aeglea BioTherapeutics (NASDAQ:AGLE) entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities in a registered direct offering for gross proceeds of ~$45M. The financing includes 10.75M shares at $1.6/sh...
-
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market PR Newswire AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company ...
-
Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q1 GAAP EPS of -$0.37. Revenue of $1.36B. For further details see: Aeglea BioTherapeutics GAAP EPS of -$0.37, revenue of $1.36B
-
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates PR Newswire Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional ...
-
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
-
Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...
-
CarMax (NYSE:KMX) drew significant attention in Tuesday's pre-market action, falling on weaker-than-expected quarterly results. Starbucks (SBUX) also took its share of the spotlight, weighed down by an analyst's downgrade. Novartis (NVS) generated headlines as well, following reports that it ...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another dive into the market this morning with a look at the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com We’ve got a reverse stock split, clinical trial...
-
Aeglea BioTherapeutics (NASDAQ:AGLE) submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of pegzilarginase to treat Arginase 1 Deficiency (ARG1-D). The company has requested FDA priority review of the biologics license application (BLA). Aeglea (AGLE) adde...
-
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on nex...
Stock Information
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
MENU
AGLE
AGLE Quote
AGLE Short
AGLE News
AGLE Articles
Get AGLE Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market PR Newswire AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company ...
-
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates PR Newswire Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional ...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another dive into the market this morning with a look at the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com We’ve got a reverse stock split, clinical trial...